Delving into the Latest Updates on Alcon Cusi SA with Synapse

Overview

Basic Info

Introduction

Alcon Cusi SA is a Spanish-based corporation that specializes in the development, production, and distribution of contact lenses. It operates as a subsidiary of Nestlé SA.

Tags

Nervous System Diseases

Eye Diseases

Other Diseases

Small molecule drug

Disease domain score

A glimpse into the focused therapeutic areas

Technology Platform

Most used technologies in drug development

Targets

Most frequently developed targets

Disease Domain	Count

Nervous System Diseases	1

Top 5 Drug Type	Count

Small molecule drug	1

Top 5 Target	Count

COXs(Cyclooxygenases)	1

Author: Cockrum, Paul C. ; Colin, J. ; Whitling, Anna ; Stadion, P. ; Amin, Dina ; Dralands, L. ; Carvolho, J. R. ; Kennedy, Margaret ; Schmidl, B. ; George, J. L. ; Bertin, Donata ; Gerl, R. ; Maugery, J. ; Strobel, J. ; Pulido, Martha ; Notivol, Ricardo ; Adank, A. ; Golcalves Filho, P. ; Vissac, L. ; Van, F. ; de Almeida, G. V. ; Assaf, J. ; Collette, P. ; Dick, B. ; Kampik, A. ; Mester, U. ; Muccioli, C. ; Adank, Paul ; Adenis, J. P. ; Hoeh, H. ; Auclin, F. ; Guthof, R. ; Fornazari, D.

BACKGROUNDIntraocular inflammation is typically treated with a combination of anti-inflammatory and anti-infective drugs. Tobramycin-dexamethasone (TD) has not been associated with any serious adverse events, indicating good tolerability.OBJECTIVEThe aims of this study were the following: (1) to demonstrate noninferiority of TD compared with dexamethasone-neomycin-polymyxin (DNP) in terms of anti-inflammatory efficacy, (2) to compare the anti-inflammatory efficacy of TD and DNP with that of a "placebo" control (antibiotic without anti-inflammatory agent), and (3) to provide additional safety data on TD.METHODSThis prospective, double-masked, parallel-group study was conducted at 22 ophthalmology clinics across Europe and Brazil. Patients aged > 18 years undergoing cataract surgery were randomly assigned, in a 2:2:1 ratio, to receive tobramycin 3 mg/mL plus dexamethasone 1 mg/mL, dexamethasone 1 mg/mL plus neomycin sulfate 3500 IU/mL plus polymyxin B sulfate 6000 IU/mL, or neomycin sulfate 3500 IU/mL plus polymyxin B sulfate 7500 IU/mL plus gramicidin 20 microg/mL. All treatments were given as 1 drop instilled in the operated eye q.i.d. for 21 days. The primary efficacy end point, intraocular inflammation (determined using the sum of scores on anterior chamber cells and aqueous flare), was assessed at days 3, 8, 14, and 21 after surgery.RESULTSA total of 271 patients were enrolled (158 women, 113 men; age range 42-90 years) (TD, 104 patients; DNP, 110 patients; and neomycin-polymyxin-gramicidin [NPG], 57 patients). Intraocular inflammation was similar in the TD and DNP groups at all time points. At days 8, 14, and 21, inflammation scores were significantly lower with TD than with NPG (all, P < 0.05). At day 8, the inflammation score was significantly lower with DNP than with NPG (P < 0.05). A greater number of patients receiving NPG experienced treatment-related ocular allergic reactions compared with patients receiving TD (P < 0.05). One patient receiving TD (1.0%) and 5 given NPG (9.0%) were withdrawn due to ocular allergic reactions. None of the patients experienced an increase in intraocular pressure > or =10 mm Hg from baseline.CONCLUSIONSIn this study of patients undergoing cataract surgery combination therapy with TD was noninferior to DNP and was well tolerated.

Clinical Drug Investigation

Prophylactic effectiveness of tobramycin-dexamethasone eye drops compared with tobramycin/vehicle eye drops in controlling post-surgical inflammation in cataract patients: Prospective, randomized, double-masked, two-arm, parallel-group, placebo-controlled, multicenter study

Author: Cockrum, Paul C. ; Whitling, Anna ; Wells, David ; Lorenzo, J. M. ; Royo, M. ; Weheler, T. ; Kennedy, Margaret ; Ruiz-Lapuente, C. ; Belfort, R. Jr ; Arias, A. ; De Laey, J. J. ; Tassignon, M. J. ; Collum, L. ; Cano, J. ; Barraquer, R. ; Amin, Dina ; O'Donoghue, E. ; Notivol, Ricardo ; Schmidl, B. ; Lobo, C. ; Behndig, A. ; Schmickler, S. ; Cohen, R. ; Schrage, N. ; Pulido, Marta

The aim was to demonstrate the superiority of TobraDex (tobramycin 3 mg/mL, dexamethasone 1 mg/mL) eye drops over Tobrex (tobramycin 3 mg/mL)/vehicle (placebo) eye drops in the prophylaxis of inflammation after cataract surgery, and to provide addnl. safety data on TobraDex.Twenty-two ophthalmol. clinics from Brazil, Belgium, Germany, Ireland, Portugal, Spain and Sweden.Prospective, randomized, double-masked, two-arm, parallel-group, placebo-controlled, multicenter study in 417 patients undergoing extracapsular cataract extraction with intraocular lens implantation.Patients were randomized (1: 1) to TobraDex or to Tobrex/vehicle.One drop of TobraDex or Tobrex was instilled in the operative eye (four times daily) on the day before surgery (day -1), one drop immediately following surgery in the operated eye (day 0), and then treatment (four times daily) was continued until day 7 (inclusive).From day 8 through day 21, patients in the TobraDex group continued with the same treatment, but patients in the Tobrex/vehicle arm received the inactive ingredient only.Efficacy was assessed at 1, 3, 8, 14 and 21 days.The primary efficacy variable was the percentage of patients without post-surgical anterior chamber inflammation (i.e. with a sum of cells and flare scores of zero) on the day 8 visit.TobraDex was significantly better (p < 0.05) than Tobrex/vehicle in controlling post-surgical inflammation at day 8 as shown by the percentage of patients with an inflammation score of zero (51% vs 21%, resp.).The percentage of patients with treatment failure was 4% vs 16% (p < 0.001) in favor of TobraDex.In the safety population (n = 415), 19% of patients reported a total of 52 adverse events while receiving TobraDex and 35.3% patients reported 103 adverse events while receiving Tobrex/vehicle.One patient receiving Tobrex/vehicle discontinued the study due to an ocular allergic reaction.No patient experienced clin. relevant changes in visual acuity, fundus parameters, cup/disk ratio or intraocular pressure related to treatment following the day of surgery.TobraDex eye drops were superior to Tobrex/vehicle in controlling post-surgical inflammation following cataract extractionTobraDex administered four times daily over 21 days post-surgery was safe and well tolerated in patients treated for the prevention of post-surgical inflammation following cataract extraction

100 Deals associated with Alcon Cusi SA

Login to view more data

100 Translational Medicine associated with Alcon Cusi SA

Login to view more data

Corporation Tree

Boost your research with our corporation tree data.

login

or

view full example data

Boost your research with our corporation tree data.

Pipeline

Pipeline Snapshot as of 10 May 2025

The statistics for drugs in the Pipeline is the current organization and its subsidiaries are counted as organizations,Early Phase 1 is incorporated into Phase 1, Phase 1/2 is incorporated into phase 2, and phase 2/3 is incorporated into phase 3

Approved

1

Login to view more data